Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

1. Dimopoulos, M.
2. Quach, H.
3. Mateos, M.-V.
4. Landgren, O.
5. Leleu, X.
6. Siegel, D.
7. Weisel, K.
8. Yang, H.
9. Klippel, Z.
10. Zahlten-Kumeli, A.
11. Usmani, S.Z.